Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Sees Large Decrease in Short Interest

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totaling 2,033 shares, a decline of 61.2% from the June 15th total of 5,246 shares. Based on an average trading volume of 80,643 shares, the short-interest ratio is presently 0.0 days.

Algernon Pharmaceuticals Price Performance

OTCMKTS AGNPF opened at $0.27 on Wednesday. Algernon Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $0.64. The firm has a 50-day moving average price of $0.31 and a 200 day moving average price of $0.15.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).